MicroRNAs in Pancreatic Cancer: biomarkers, prognostic, and therapeutic modulators
department or school: Medicine, Faculty of
department or school: Non UBC
department or school: Pathology and Laboratory Medicine, Department of
data provider: DSpace
identifier citation: BMC Cancer. 2019 Nov 21;19(1):1130
rights copyright: The Author(s).
creator: Daoud, Afra Z
creator: Mulholland, Eoghan J
creator: Cole, Grace
creator: McCarthy, Helen O
issued: 2019-11-21T19:21:37Z
issued: 2019-11-21
description: A severe lack of early diagnosis coupled with resistance to most available therapeutic options renders pancreatic cancer as a major clinical concern. The limited efficacy of current treatments necessitates the development of novel therapeutic strategies that are based on an understanding of the molecular mechanisms involved in pancreatic cancer progression. MicroRNAs (miRNAs) are non-coding small RNAs that regulate the expression of multiple proteins in the post-translation process and thus have promise as biomarkers, prognostic agents, and as advanced pancreatic therapies. Profiling of deregulated miRNAs in pancreatic cancer can correlate to diagnosis, indicate optimal treatment and predict response to therapy. Furthermore, understanding the main effector genes in pancreatic cancer along with downstream pathways can identify possible miRNAs as therapeutic candidates. Additionally, obstacles to the translation of miRNAs into the clinic are also considered. Distinct miRNA expression profiles can correlate to stages of malignant pancreatic disease, and hold potential as biomarkers, prognostic markers and clinical targets. However, a limited understanding and validation of the specific role of such miRNAs stunts clinical application. Target prediction using algorithms provides a wide range of possible targets, but these miRNAs still require validation through pre-clinical studies to determine the knock-on genetic effects.
aggregated CHO: https://circle.library.ubc.ca/rest/handle/2429/72351
note: DEBATE Open AccessMicroRNAs in Pancreatic Cancer:biomarkers, prognostic, and therapeuticmodulatorsAfra Z. Daoud1†, Eoghan J. Mulholland2†, Grace Cole3,4 and Helen O. McCarthy1*AbstractA severe lack of early diagnosis coupled with resistance to most available therapeutic options renders pancreaticcancer as a major clinical concern. The limited efficacy of current treatments necessitates the development of noveltherapeutic strategies that are based on an understanding of the molecular mechanisms involved in pancreaticcancer progression. MicroRNAs (miRNAs) are non-coding small RNAs that regulate the expression of multipleproteins in the post-translation process and thus have promise as biomarkers, prognostic agents, and as advancedpancreatic therapies.Profiling of deregulated miRNAs in pancreatic cancer can correlate to diagnosis, indicate optimal treatment andpredict response to therapy. Furthermore, understanding the main effector genes in pancreatic cancer along withdownstream pathways can identify possible miRNAs as therapeutic candidates. Additionally, obstacles to thetranslation of miRNAs into the clinic are also considered.Distinct miRNA expression profiles can correlate to stages of malignant pancreatic disease, and hold potential asbiomarkers, prognostic markers and clinical targets. However, a limited understanding and validation of the specificrole of such miRNAs stunts clinical application. Target prediction using algorithms provides a wide range of possibletargets, but these miRNAs still require validation through pre-clinical studies to determine the knock-on geneticeffects.Keywords: Pancreatic Cancer, microRNA, Biomarker, Prognosis, Chemoresistance, Gene therapyBackgroundIntroduction to Pancreatic CancerCancer is a devastating disease, and of the 18 million di-agnosed globally in 2018, approximately 500,000 caseswere pancreatic [1]. Furthermore, pancreatic cancer(PC), in all forms, has the lowest survival rate of anycancer type; with less than 1% overall…
has type: Article
is shown at: 10.14288/1.0385814
language: eng
peer review status: Reviewed
provider: Vancouver : University of British Columbia Library
publisher: BioMed Central
publisher DOI: 10.1186/s12885-019-6284-y
rights: Attribution 4.0 International (CC BY 4.0)
rights URI: http://creativecommons.org/licenses/by/4.0/
scholar level: Faculty
subject: Pancreatic Cancer
subject: microRNA
subject: Biomarker
subject: Prognosis
subject: Chemoresistance
subject: Gene therapy
type: Text
identifier URI: http://hdl.handle.net/2429/72351